Scalper1 News
Five drug companies including NewLink Genetics (NLNK), Juno Therapeutics (JUNO) and Intrexon (XON) reported quarterly results after the close on Monday, but some investors seemed to be more focused on the companies’ development updates than their actual earnings. Depomed Misses Depomed (DEPO) widened its loss to an adjusted 13 cents a share from last year’s 1-cent loss. Analysts were expecting earnings of a penny. Revenue fell 58% to $32.2 Scalper1 News
Scalper1 News